Provide updates on the latest expertise, instrumentation, and standards in enumerating Circulating Biomarkers (CBM).
The future of precision medicine (PM) is being shaped by the ability to harness Circulating Biomarkers (CBM)—a powerful class of biological indicators that provide real-time insights into disease progression, treatment response, and therapeutic targeting. From cancer to neurological disorders, CBM has the potential to revolutionise early diagnosis, risk stratification, and personalised therapy.
However, significant challenges remain in standardisation, clinical translation, and commercial adoption of CBM-based technologies. This symposium brings together leading scientists, clinicians and industry innovators to explore cutting-edge advancements and real-world applications of CBM research.
This symposium aims to enhance the understanding and application of liquid biopsy in personalised medicine for oncology and neurology.
It will update state-of-the-art methods for identifying and characterising CBM using tools like liquid biopsy, genomics, proteomics, and advanced imaging.
The event will highlight recent research and discuss CTCs, exosomes, and cfDNA for early detection, diagnosis, prognosis, and treatment monitoring of cancers and neurological disorders.
